Auxly Cannabis Group Inc (TSE:XLY)
TSX:XLY
Top Page
Auxly Cannabis Group
(TSX:XLY)
Select Model
Select Model
Rating:67Neutral
Price Target:
C$0.13
▼(-7.14% Downside)
Action:ReiteratedDate:03/28/26
The score is driven primarily by improving fundamentals—significant leverage reduction and stronger operating/free cash flow—tempered by uneven operating profitability (a return to operating losses in 2025). Technicals are modestly supportive, and valuation is attractive due to the low P/E.
Positive Factors
Balance-sheet repair / lower leverage
Auxly's deleveraging to roughly 0.32 debt-to-equity meaningfully lowers financial risk and interest burden, improving capital flexibility. This stronger capitalization supports supply agreements, operational stability, and reinvestment capacity, improving resilience over the next several quarters.
Negative Factors
Volatile operating profitability
The reversion to operating losses in 2025 after a profitable 2024 highlights unstable core operating performance. Persistent or recurring negative operating margins would erode cash generation, limit reinvestment capacity, and raise execution risk for sustainable profitability over the coming months.
Read all positive and negative factors
Positive Factors
Negative Factors
Balance-sheet repair / lower leverage
Auxly's deleveraging to roughly 0.32 debt-to-equity meaningfully lowers financial risk and interest burden, improving capital flexibility. This stronger capitalization supports supply agreements, operational stability, and reinvestment capacity, improving resilience over the next several quarters.
Read all positive factors
Auxly Cannabis Group (XLY) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$168.38M
Dividend YieldN/A
Average Volume (3M)979.68K
Price to Earnings (P/E)4.6
Beta (1Y)0.98
Revenue Growth27.38%
EPS GrowthN/A
CountryCA
Employees388
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)<0.01
Shares Outstanding1,403,150,400
10 Day Avg. Volume1,296,089
30 Day Avg. Volume979,678
Financial Highlights & Ratios
PEG Ratio-0.01
Price to Book (P/B)1.09
Price to Sales (P/S)1.27
P/FCF Ratio8.25
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.01
Revenue Forecast (FY)C$163.90M
Auxly Cannabis Group Business Overview & Revenue Model
Company Description
Auxly Cannabis Group Inc. operates as a consumer-packaged goods company in the cannabis products market in Canada. The company focuses on developing, manufacturing, and distributing cannabis products for wellness and recreational consumers. It off...
How the Company Makes Money
Auxly primarily makes money by selling branded cannabis products into the Canadian regulated adult-use market. Revenue is generated when Auxly (or its operating subsidiaries) supply finished goods—such as dried flower, pre-rolls, vape products, an...
Auxly Cannabis Group Financial Statement Overview
Summary
Income Statement
54
Neutral
Balance Sheet
70
Positive
Cash Flow
76
Positive
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 151.48M | 122.33M | 101.08M | 94.47M | 83.83M |
| Gross Profit | 24.64M | 59.93M | 21.28M | 17.92M | 19.29M |
| EBITDA | -12.98M | 24.38M | -10.89M | -93.40M | -13.64M |
| Net Income | 41.85M | -16.35M | -44.51M | -130.29M | -45.91M |
Balance Sheet | |||||
| Total Assets | 271.64M | 261.53M | 261.90M | 331.82M | 450.42M |
| Cash, Cash Equivalents and Short-Term Investments | 32.67M | 18.50M | 15.75M | 14.78M | 14.89M |
| Total Debt | 57.65M | 68.47M | 159.04M | 193.59M | 190.10M |
| Total Liabilities | 94.06M | 145.87M | 210.86M | 246.13M | 242.31M |
| Stockholders Equity | 177.58M | 115.66M | 51.05M | 90.41M | 212.52M |
Cash Flow | |||||
| Free Cash Flow | 23.37M | 14.02M | 6.61M | -11.67M | -50.01M |
| Operating Cash Flow | 25.89M | 16.78M | 8.21M | -2.48M | -49.63M |
| Investing Cash Flow | -2.46M | -445.00K | -1.56M | 1.18M | 17.33M |
| Financing Cash Flow | -9.81M | -13.59M | -5.68M | 1.18M | 26.40M |
Auxly Cannabis Group Technical Analysis
Positive
0.14
Price Trends
0.13
Positive
0.14
Positive
0.14
Negative
Market Momentum
<0.01
Positive
57.55
Neutral
33.33
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:XLY, the sentiment is Positive. The current price of 0.14 is above the 20-day moving average (MA) of 0.13, above the 50-day MA of 0.13, and below the 200-day MA of 0.14, indicating a neutral trend. The MACD of <0.01 indicates Positive momentum. The RSI at 57.55 is Neutral, neither overbought nor oversold. The STOCH value of 33.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:XLY.
Auxly Cannabis Group Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
67 Neutral | C$168.38M | 4.61 | 27.19% | ― | 27.38% | ― | |
61 Neutral | C$1.35B | -104.58 | -0.87% | ― | 22.20% | ― | |
56 Neutral | C$1.67B | -13.95 | -9.71% | ― | 4.27% | 3.41% | |
54 Neutral | C$269.95M | 3.90 | 4.86% | ― | 62.15% | 60.50% | |
52 Neutral | C$272.77M | 44.94 | -7.78% | ― | 23.87% | -19.57% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | C$678.15M | -2.15 | -52.88% | ― | -0.67% | 58.98% |
* Healthcare Sector Average
TSE:XLY
Auxly Cannabis Group
0.14
0.06
75.00%
TSE:WEED
Canopy Growth
1.49
-0.14
-8.59%
TSE:OGI
Organigram Global
1.98
0.53
36.55%
TSE:ACB
Aurora Cannabis
4.89
-1.12
-18.64%
TSE:CRON
Cronos Group
3.55
1.10
44.90%
TSE:TRUL
Trulieve Cannabis
8.91
4.12
86.01%
Auxly Cannabis Group Corporate Events
Business Operations and StrategyM&A TransactionsPrivate Placements and Financing
Auxly’s Bid for Ayurcann Fails but Back-Up Role Secures Fees and Repayment
Positive
Apr 13, 2026
Auxly Cannabis Group reported that its stalking horse bid for the assets of Ayurcann Holdings Corp. was not chosen as the winning offer in a court-supervised sale, but has been designated as the back-up bid if the selected transaction fails to clo...
Business Operations and StrategyFinancial DisclosuresM&A Transactions
Auxly Boosts 2025 Profitability, Strengthens Balance Sheet and Expands Brand Portfolio
Positive
Mar 26, 2026
Auxly reported strong financial performance for 2025, with net revenue rising 24% to $151.5 million and gross margin on finished cannabis inventory sold improving to 54%. Adjusted EBITDA jumped 64% to $43.8 million, yielding a 29% margin, while ne...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.